What is WO2000062778, and how does it relate to dasatinib?
WO2000062778 is a patent publication from the WO (PCT) system that is associated with claims covering aspects of the underlying intellectual property landscape around dasatinib. Dasatinib is a small-molecule drug marketed by Bristol Myers Squibb (BMS) under the brand Sprycel. [1]
Who holds the dasatinib-related patent rights for WO2000062778?
Bristol Myers Squibb is closely associated with dasatinib’s commercialization and core drug-related IP. However, a WO publication like WO2000062778 can list inventors and applicants on the original filing, and the rights can later shift across jurisdictions through assignments. The exact current assignee for WO2000062778 depends on the specific record shown for that publication in the patent database. [1]
When does the patent typically expire (and what affects the expiration date)?
Patent expiration for drug-related filings usually follows rules such as the standard term counted from the priority date, plus any possible extensions that depend on the country (for example, patent term adjustments/extended protection for regulatory delays). The actual expiration date for WO2000062778 can differ by jurisdiction because of differing national-phase timelines and whether any adjustments/extensions apply. The most reliable way to get the exact date is to check the “expiration/term” fields for each country entry tied to that WO filing. [1]
Is there a separate “patent” vs “WO publication” issue with WO2000062778?
Yes. WO numbers identify the international PCT publication. That WO application can enter national or regional phases (for example, Europe, US, etc.), where it becomes individual country patents with their own grant status and expiration dates. So “WO2000062778” by itself does not automatically tell you a single worldwide expiration date; you need to map it to the countries where it granted. [1]
Where to check the exact expiration/validity for the specific dasatinib patent in your country?
The fastest path is to look up WO2000062778 in a patent database and then check the list of:
- publication and priority dates,
- national/regional filings (EP/US/etc.),
- grant status,
- and the “expiration” or “term” details per jurisdiction. [1]
Key point for researchers or litigators looking up this exact citation
If your goal is to determine whether WO2000062778 blocks generic or biosimilar entry for dasatinib in a particular market, you need the country-specific status (granted vs pending), the exact claims being asserted, and whether exclusivity is extended by local regulatory protection or later patents that may be more directly tied to the commercial product. [1]
---
Sources
[1] https://patentscope.wipo.int/ (Search result/page for WO2000062778 in the WIPO PATENTSCOPE database)